Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances

Orchestra BioMed Holdings, Inc., in collaboration with Medtronic, has announced significant advancements in the treatment of uncontrolled hypertension through their Atrioventricular Interval Modulation (AVIM) Therapy. The joint presentation at the 2025 Innovation in Cardiology Intervention (ICI) meeting in Tel Aviv showcased the strategic partnership’s success, underlining the potential impact on millions of patients worldwide suffering from hypertensive heart disease. 

Orchestra BioMed is a leading biomedical innovation company known for accelerating high-impact technologies. Currently, the company’s flagship products, AVIM Therapy and the Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), target multi-billion-dollar markets. AVIM Therapy, a cutting-edge bioelectronic treatment, aims to offer a breakthrough in managing hypertension, a major global health risk. This therapy, which can be delivered through a pacemaker firmware upgrade, promises immediate and sustained blood pressure reductions. Having received FDA Breakthrough Device Designation, it holds promise for 7.7 million U.S. patients struggling with uncontrolled hypertension. The collaboration with Medtronic, a medical device industry giant, highlights the strategic efforts to commercialize this promising treatment. 

The advancements in AVIM Therapy underscore the importance of innovation and collaboration between leading biomedical companies like Orchestra BioMed and Medtronic. As these therapies move through pivotal clinical trials, they have the potential to transform the landscape of hypertension treatment and beyond, bringing significant improvements to patient care and offering new opportunities within the life sciences industry.